


CLINICAL PROGRESSION AND PATIENT OUTCOMES¹

- The evolution of Fabry disease cardiac involvement can be seen in the figure below along with the optimal treatment window for expected treatment efficacy
- Cardiac disease staging can be determined by clinical assessment, imaging and assessment of biomarkers



ECG = electrocardiography; ERT = enzyme replacement therapy; GLS = global longitudinal strain; LGE = late gadolinium enhancement; LVH = left ventricular hypertrophy; lyso-Gb3 = globotriaosylsphingosine; MBF = myocardial blood flow; NT-proBNP = NT-probrain natriuretic peptide.

References : (1) Pieroni M, et al. J Am Coll Cardiol. 2021;77:922–36.

MAT-XU-2300065 (v4.0)

Date of Preparation : February 2024